According to @demishassabis on X, Isomorphic Labs’ AI-driven drug design engine has advanced the state of the art across key in‑silico discovery benchmarks, showing major gains in accuracy and capabilities critical for computational drug design (source: Demis Hassabis on X, Feb 10, 2026). As reported by the same post, the effort is led by Max Jaderberg and the Isomorphic Labs team, implying improvements that could accelerate hit identification and lead optimization workflows for pharma R&D. According to the X post, these benchmark gains suggest stronger structure-based modeling and generative design performance, offering business opportunities in faster preclinical triage, reduced wet‑lab iterations, and scalable virtual screening partnerships with biopharma.